ZA200502700B - 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. - Google Patents
1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. Download PDFInfo
- Publication number
- ZA200502700B ZA200502700B ZA200502700A ZA200502700A ZA200502700B ZA 200502700 B ZA200502700 B ZA 200502700B ZA 200502700 A ZA200502700 A ZA 200502700A ZA 200502700 A ZA200502700 A ZA 200502700A ZA 200502700 B ZA200502700 B ZA 200502700B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- hydrogen
- oxo
- group
- substituents
- Prior art date
Links
- 125000001424 substituent group Chemical group 0.000 claims description 126
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 125000005843 halogen group Chemical group 0.000 claims description 60
- 125000004043 oxo group Chemical group O=* 0.000 claims description 56
- 125000000304 alkynyl group Chemical group 0.000 claims description 53
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 53
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 49
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 49
- -1 nitro, oxy Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 46
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 43
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
- PSDYQSWHANEKRV-UHFFFAOYSA-N [S]N Chemical compound [S]N PSDYQSWHANEKRV-UHFFFAOYSA-N 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical group CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N CH2-hydantoin Natural products O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- TUDYPXFSYJRWDP-UHFFFAOYSA-N methoxy methyl carbonate Chemical group COOC(=O)OC TUDYPXFSYJRWDP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 32
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 5
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- QRASROYCJPXCCL-SBJJXXPASA-N (E)-3-(2-amino-4-chloro-5-methoxyphenyl)-1-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2[C@@H](CN(CC=3C=CC(F)=CC=3)CC2)C)=C1N QRASROYCJPXCCL-SBJJXXPASA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- OMKWFGOUVCFSCC-BJMVGYQFSA-N 1-[4-chloro-2-[(e)-3-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]-3-cyano-1-methylsulfanylthiourea Chemical compound N#CNC(=S)N(SC)C1=CC=C(Cl)C=C1\C=C\C(=O)N1C(C)CN(CC=2C=CC(F)=CC=2)CC1 OMKWFGOUVCFSCC-BJMVGYQFSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- FGWGUTDBNUTFLC-RUDMXATFSA-N 2-[4-chloro-2-[(e)-3-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]-1-cyanoguanidine Chemical compound C1CN(C(=O)\C=C\C=2C(=CC=C(Cl)C=2)NC(=N)NC#N)C(C)CN1CC1=CC=C(F)C=C1 FGWGUTDBNUTFLC-RUDMXATFSA-N 0.000 description 1
- VLJHNNJRRSLTLE-UHFFFAOYSA-N 2-oxoimidazolidine-1-carboxylic acid Chemical compound OC(=O)N1CCNC1=O VLJHNNJRRSLTLE-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WZEFFFYJQFGJBZ-QPGLYAHGSA-N 3-[5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-1,3-diazaspiro[4.4]nonane-2,4-dione Chemical compound O=C1NC2(CCCC2)C(=O)N1C=1C=C(Cl)C(OC)=CC=1\C=C\C(=O)N([C@@H](C1)C)CCN1CC1=CC=C(F)C=C1 WZEFFFYJQFGJBZ-QPGLYAHGSA-N 0.000 description 1
- DACKYLWJNMGQNC-UHFFFAOYSA-N 4-ethynyl-1-methylpiperidin-4-ol Chemical compound CN1CCC(O)(C#C)CC1 DACKYLWJNMGQNC-UHFFFAOYSA-N 0.000 description 1
- GVZFMFFUAZKMOB-UHFFFAOYSA-N 4-ethynylpiperidin-4-ol Chemical compound C#CC1(O)CCNCC1 GVZFMFFUAZKMOB-UHFFFAOYSA-N 0.000 description 1
- TWQKRHVLMLNOOM-VDZSZVPASA-N 5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]-n-methoxy-n-methylbenzamide Chemical compound CON(C)C(=O)C1=CC(Cl)=CC=C1\C=C\C(=O)N1[C@H](C)CN(CC=2C=CC(F)=CC=2)CC1 TWQKRHVLMLNOOM-VDZSZVPASA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GNMSLDIYJOSUSW-LURJTMIESA-N N-acetyl-L-proline Chemical compound CC(=O)N1CCC[C@H]1C(O)=O GNMSLDIYJOSUSW-LURJTMIESA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- SOQTZVDCTDWUPS-JHCSKLMMSA-N [5-chloro-2-[(e)-3-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]urea Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)\C=C\C=2C(=CC(Cl)=CC=2)NC(N)=O)N1CC1=CC=C(F)C=C1 SOQTZVDCTDWUPS-JHCSKLMMSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001727 carbonic acid monoesters Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- ZTVRVFGSLAYBEF-UHFFFAOYSA-N ethyl 4-formamidopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(NC=O)CC1 ZTVRVFGSLAYBEF-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QTNLSMSKXZFKML-UXBLZVDNSA-N methyl 5-chloro-2-[(e)-3-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]benzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1\C=C\C(=O)N1C(C)CN(CC=2C=CC(F)=CC=2)CC1 QTNLSMSKXZFKML-UXBLZVDNSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical group CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- PXKZVCOKJFOTQY-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)acetamide Chemical compound C1CC(NC(=O)C)CCN1CC1=CC=CC=C1 PXKZVCOKJFOTQY-UHFFFAOYSA-N 0.000 description 1
- WHTUWYBGTLLCKF-UHFFFAOYSA-N n-(1-methylpiperidin-4-yl)acetamide Chemical compound CN1CCC(NC(C)=O)CC1 WHTUWYBGTLLCKF-UHFFFAOYSA-N 0.000 description 1
- MQODCWGPPFRIEF-AEVNEEFTSA-N n-[2-[(e)-3-[(2r)-2-(aminomethyl)-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-3-oxoprop-1-enyl]-5-chlorophenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1\C=C\C(=O)N1[C@H](CN)CN(CC=2C=CC(F)=CC=2)CC1 MQODCWGPPFRIEF-AEVNEEFTSA-N 0.000 description 1
- OKPDPHQVVCXCIO-VSRDTVRMSA-N n-[3-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]naphthalen-2-yl]acetamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC3=CC=CC=C3C=2)NC(C)=O)C)N1CC1=CC=C(F)C=C1 OKPDPHQVVCXCIO-VSRDTVRMSA-N 0.000 description 1
- WMNVCJHUWOKRDG-BJMVGYQFSA-N n-[4-chloro-2-[(e)-3-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C1CN(C(=O)\C=C\C=2C(=CC=C(Cl)C=2)NC(C)=O)C(C)CN1CC1=CC=C(F)C=C1 WMNVCJHUWOKRDG-BJMVGYQFSA-N 0.000 description 1
- LPZSTSAAMPGUEG-ICKBMGCOSA-N n-[5-chloro-2-[(e)-3-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC(Cl)=CC=2)NC(C)=O)CC)N1CC1=CC=C(F)C=C1 LPZSTSAAMPGUEG-ICKBMGCOSA-N 0.000 description 1
- VODYKHASXWEHLJ-SBJJXXPASA-N n-[5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]-4-(trifluoromethoxy)phenyl]acetamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC(Cl)=C(OC(F)(F)F)C=2)NC(C)=O)C)N1CC1=CC=C(F)C=C1 VODYKHASXWEHLJ-SBJJXXPASA-N 0.000 description 1
- MXFQQMJDQHFGCV-MTCRFPMVSA-N n-[5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]morpholine-4-carboxamide Chemical compound C1COCCN1C(=O)NC=1C=C(Cl)C(OC)=CC=1\C=C\C(=O)N([C@@H](C1)C)CCN1CC1=CC=C(F)C=C1 MXFQQMJDQHFGCV-MTCRFPMVSA-N 0.000 description 1
- GYQIZRVGOBQSGG-QPGLYAHGSA-N n-[5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]pyrrolidine-1-carboxamide Chemical compound C1CCCN1C(=O)NC=1C=C(Cl)C(OC)=CC=1\C=C\C(=O)N([C@@H](C1)C)CCN1CC1=CC=C(F)C=C1 GYQIZRVGOBQSGG-QPGLYAHGSA-N 0.000 description 1
- AELMJFWYSUOUGF-MTCRFPMVSA-N n-[5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]-4-morpholin-4-ylphenyl]acetamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC(Cl)=C(N3CCOCC3)C=2)NC(C)=O)C)N1CC1=CC=C(F)C=C1 AELMJFWYSUOUGF-MTCRFPMVSA-N 0.000 description 1
- DUFKTZBQJIHIAQ-VGZDNEPHSA-N n-[5-chloro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC(Cl)=CC=2)NC(C)=O)C)N1CC1=CC=C(F)C=C1 DUFKTZBQJIHIAQ-VGZDNEPHSA-N 0.000 description 1
- TXFDENXEXABBDW-NGXUEJOTSA-N n-[5-chloro-2-[(e)-3-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]acetamide Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2[C@@H](CN(CC=3C=CC(F)=CC=3)[C@@H](C)C2)C)=C1NC(C)=O TXFDENXEXABBDW-NGXUEJOTSA-N 0.000 description 1
- OGAAHLSBWGMDAH-MEQKGCOVSA-N n-[5-chloro-2-[(e)-3-[(2s)-4-[(4-fluorophenyl)methyl]-2-(hydroxymethyl)piperazin-1-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]methanesulfonamide Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2[C@@H](CN(CC=3C=CC(F)=CC=3)CC2)CO)=C1NS(C)(=O)=O OGAAHLSBWGMDAH-MEQKGCOVSA-N 0.000 description 1
- LCDYBFVSPXSNHQ-OWLMGLOSSA-N n-[5-chloro-2-[(e)-3-[(2s)-4-[(4-fluorophenyl)methyl]-2-(hydroxymethyl)piperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1\C=C\C(=O)N1[C@H](CO)CN(CC=2C=CC(F)=CC=2)CC1 LCDYBFVSPXSNHQ-OWLMGLOSSA-N 0.000 description 1
- KQRZTSQFPNLYIL-KVKRHKIDSA-N n-[5-chloro-2-[(e)-3-[(2s,5s)-4-[(4-fluorophenyl)methyl]-5-methyl-2-(phenylmethoxymethyl)piperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C([C@H]1N(C[C@@H](N(C1)CC=1C=CC(F)=CC=1)C)C(=O)\C=C\C=1C(=CC(Cl)=CC=1)NC(C)=O)OCC1=CC=CC=C1 KQRZTSQFPNLYIL-KVKRHKIDSA-N 0.000 description 1
- IFTAKZIIEOCMPH-UXBLZVDNSA-N n-[5-chloro-2-[(e)-3-[4-[(4-chlorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C1CN(C(=O)\C=C\C=2C(=CC(Cl)=CC=2)NC(C)=O)C(C)CN1CC1=CC=C(Cl)C=C1 IFTAKZIIEOCMPH-UXBLZVDNSA-N 0.000 description 1
- HIDICENMVRNHJQ-CSKARUKUSA-N n-[5-chloro-2-[(e)-3-[4-[(4-cyanophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C1CN(C(=O)\C=C\C=2C(=CC(Cl)=CC=2)NC(C)=O)C(C)CN1CC1=CC=C(C#N)C=C1 HIDICENMVRNHJQ-CSKARUKUSA-N 0.000 description 1
- VRHDKJQVCPDYJB-WEVVVXLNSA-N n-[5-chloro-2-[(e)-3-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1\C=C\C(=O)N1CCN(CC=2C=CC(F)=CC=2)CC1 VRHDKJQVCPDYJB-WEVVVXLNSA-N 0.000 description 1
- DFEHALWAKUXBPW-PYUISTEWSA-N n-[5-chloro-4-ethoxy-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C1=C(Cl)C(OCC)=CC(\C=C\C(=O)N2[C@@H](CN(CC=3C=CC(F)=CC=3)CC2)C)=C1NC(C)=O DFEHALWAKUXBPW-PYUISTEWSA-N 0.000 description 1
- JTFRLPSCLRRZFU-SBJJXXPASA-N n-[5-chloro-4-fluoro-2-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]phenyl]methanesulfonamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC(Cl)=C(F)C=2)NS(C)(=O)=O)C)N1CC1=CC=C(F)C=C1 JTFRLPSCLRRZFU-SBJJXXPASA-N 0.000 description 1
- MVIVWOSZVYNMQN-RUJXFNLJSA-N n-[6-[(e)-3-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-3-oxoprop-1-enyl]quinolin-7-yl]acetamide Chemical compound C([C@H](N(CC1)C(=O)\C=C\C=2C(=CC3=NC=CC=C3C=2)NC(C)=O)C)N1CC1=CC=C(F)C=C1 MVIVWOSZVYNMQN-RUJXFNLJSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ICTGBOFCIDHVPA-UHFFFAOYSA-N n-methylsulfonylmethanesulfonamide Chemical compound CS(=O)(=O)NS(C)(=O)=O ICTGBOFCIDHVPA-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- JMCVUWLHZZYXLA-UHFFFAOYSA-N tert-butyl 4-ethynyl-2-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#C)CC1O JMCVUWLHZZYXLA-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0224917.5A GB0224917D0 (en) | 2002-10-25 | 2002-10-25 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200502700B true ZA200502700B (en) | 2006-05-31 |
Family
ID=9946616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200502700A ZA200502700B (en) | 2002-10-25 | 2005-04-04 | 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7645760B2 (ja) |
| EP (1) | EP1558594A2 (ja) |
| JP (1) | JP2006505575A (ja) |
| KR (1) | KR20050065620A (ja) |
| CN (2) | CN100554257C (ja) |
| AR (1) | AR043055A1 (ja) |
| AU (1) | AU2003296559B2 (ja) |
| BR (1) | BR0315662A (ja) |
| CA (1) | CA2502633C (ja) |
| EC (1) | ECSP055745A (ja) |
| GB (1) | GB0224917D0 (ja) |
| MX (1) | MXPA05004348A (ja) |
| NO (1) | NO20052487D0 (ja) |
| PE (1) | PE20040779A1 (ja) |
| PL (1) | PL374893A1 (ja) |
| RU (1) | RU2347782C2 (ja) |
| TW (1) | TW200420545A (ja) |
| WO (1) | WO2004037796A2 (ja) |
| ZA (1) | ZA200502700B (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| SE0400440D0 (sv) * | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Cinnamic Amides |
| SE0400441D0 (sv) | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Benzofurans and Indols |
| GB0409236D0 (en) * | 2004-04-26 | 2004-05-26 | Novartis Ag | Organic compounds |
| US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| CN101007794B (zh) * | 2006-01-26 | 2010-09-01 | 中国科学院上海药物研究所 | N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途 |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
| TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| RS53705B1 (en) * | 2010-01-29 | 2015-04-30 | Otsuka Pharmaceutical Co., Ltd. | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| EP2883870B8 (en) * | 2012-08-08 | 2019-01-23 | Mitsubishi Tanabe Pharma Corporation | Method for producing 1,4-benzoxazine compound |
| WO2014102802A1 (en) * | 2012-12-30 | 2014-07-03 | Hadasit Medical Research Services And Development Ltd. | Alginate compositions and uses thereof |
| MA38837B1 (fr) * | 2013-07-18 | 2018-10-31 | Novartis Ag | Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique |
| US9776979B2 (en) * | 2013-09-26 | 2017-10-03 | Sanford-Burnham Medical Research Institute | EBI2 modulators |
| BR112017015455A2 (pt) * | 2015-01-20 | 2018-01-23 | Novartis Ag | agentes de imagiologia pet |
| US20230052528A1 (en) * | 2019-11-22 | 2023-02-16 | The Regents Of The University Of California | Taspase1 inhibitors and uses thereof |
| CN115210225A (zh) | 2019-11-28 | 2022-10-18 | 拜耳公司 | 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60139646A (ja) * | 1983-12-27 | 1985-07-24 | Otsuka Pharmaceut Factory Inc | ナフタレン誘導体 |
| JPS6219577A (ja) * | 1985-07-16 | 1987-01-28 | Kanebo Ltd | 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物 |
| US5380726A (en) * | 1993-01-15 | 1995-01-10 | Ciba-Geigy Corporation | Substituted dialkylthio ethers |
| FR2725445B1 (fr) * | 1994-10-10 | 1996-10-31 | Adir | Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2000086603A (ja) * | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体 |
| US6110922A (en) * | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| CN1575283A (zh) * | 2001-10-22 | 2005-02-02 | 辉瑞产品公司 | 具有ccr1受体拮抗剂活性的哌嗪衍生物 |
-
2002
- 2002-10-25 GB GBGB0224917.5A patent/GB0224917D0/en not_active Ceased
-
2003
- 2003-10-21 TW TW092129162A patent/TW200420545A/zh unknown
- 2003-10-23 AR ARP030103870A patent/AR043055A1/es not_active Application Discontinuation
- 2003-10-23 PE PE2003001076A patent/PE20040779A1/es not_active Application Discontinuation
- 2003-10-24 PL PL03374893A patent/PL374893A1/xx not_active Application Discontinuation
- 2003-10-24 MX MXPA05004348A patent/MXPA05004348A/es active IP Right Grant
- 2003-10-24 CN CNB2003801020110A patent/CN100554257C/zh not_active Expired - Fee Related
- 2003-10-24 EP EP03809328A patent/EP1558594A2/en not_active Withdrawn
- 2003-10-24 KR KR1020057006954A patent/KR20050065620A/ko active IP Right Grant
- 2003-10-24 BR BR0315662-1A patent/BR0315662A/pt not_active IP Right Cessation
- 2003-10-24 AU AU2003296559A patent/AU2003296559B2/en not_active Ceased
- 2003-10-24 CA CA2502633A patent/CA2502633C/en not_active Expired - Fee Related
- 2003-10-24 US US10/532,331 patent/US7645760B2/en not_active Expired - Fee Related
- 2003-10-24 JP JP2004545990A patent/JP2006505575A/ja active Pending
- 2003-10-24 WO PCT/EP2003/011848 patent/WO2004037796A2/en active Application Filing
- 2003-10-24 CN CNA2009101474324A patent/CN101570517A/zh active Pending
- 2003-10-24 RU RU2005115964/04A patent/RU2347782C2/ru not_active IP Right Cessation
-
2005
- 2005-04-04 ZA ZA200502700A patent/ZA200502700B/en unknown
- 2005-04-25 EC EC2005005745A patent/ECSP055745A/es unknown
- 2005-05-24 NO NO20052487A patent/NO20052487D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050065620A (ko) | 2005-06-29 |
| CN101570517A (zh) | 2009-11-04 |
| CN1708489A (zh) | 2005-12-14 |
| US20060173004A1 (en) | 2006-08-03 |
| AU2003296559B2 (en) | 2007-11-01 |
| NO20052487L (no) | 2005-05-24 |
| PL374893A1 (en) | 2005-11-14 |
| ECSP055745A (es) | 2005-07-06 |
| NO20052487D0 (no) | 2005-05-24 |
| PE20040779A1 (es) | 2004-12-21 |
| CA2502633C (en) | 2011-02-01 |
| RU2347782C2 (ru) | 2009-02-27 |
| GB0224917D0 (en) | 2002-12-04 |
| AU2003296559A1 (en) | 2004-05-13 |
| RU2005115964A (ru) | 2006-01-27 |
| US7645760B2 (en) | 2010-01-12 |
| TW200420545A (en) | 2004-10-16 |
| EP1558594A2 (en) | 2005-08-03 |
| WO2004037796A2 (en) | 2004-05-06 |
| CA2502633A1 (en) | 2004-05-06 |
| MXPA05004348A (es) | 2005-08-02 |
| CN100554257C (zh) | 2009-10-28 |
| JP2006505575A (ja) | 2006-02-16 |
| WO2004037796A3 (en) | 2004-06-17 |
| BR0315662A (pt) | 2005-08-30 |
| AR043055A1 (es) | 2005-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200502700B (en) | 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. | |
| AU715841B2 (en) | 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands | |
| JP4057244B2 (ja) | 細胞接着阻害抗炎症および免疫抑制化合物 | |
| DE69431974T2 (de) | Benzamid-Derivate und ihre Verwendung als Vasopressin-Antagonisten | |
| CA1109867A (en) | Synthesis of 2-keto-1,4-diazacycloalkanes | |
| KR100307050B1 (ko) | 신규피라졸유도체,그의제조방법및그를함유하는제약학적조성물 | |
| AU774564B2 (en) | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | |
| US7683079B2 (en) | 4-aminopiperidine derivatives | |
| DE69417427T2 (de) | Indol- und indolin-derivate als 5ht1d rezeptor antagonisten | |
| JP2006505575A5 (ja) | ||
| IE914293A1 (en) | N-substituted lactams useful as cholecystokinin antagonists | |
| JP3254205B2 (ja) | タキキニンアンタゴニストとしての３−アゼチジニルアルキルピペリジンまたは−ピロリジン | |
| CA2695088A1 (en) | Novel piperazine amide derivatives | |
| WO2004113301A1 (en) | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | |
| JP2006522792A (ja) | ４−フェニル−ピペリジン化合物およびそのオピオイド受容体のモジュレーターとしての使用 | |
| US20110092698A1 (en) | Novel heterocyclyl compounds | |
| CA2450271A1 (en) | Novel phenylalkyl diamine and amide analogs | |
| JP3161892B2 (ja) | インドール−７−カルボキサミド誘導体 | |
| US5585374A (en) | Amide derivatives | |
| US6878700B1 (en) | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | |
| US5314885A (en) | Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents | |
| CA2189964A1 (en) | Novel diaminomethylidene derivative | |
| US20040116518A1 (en) | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | |
| JP2918508B2 (ja) | アゼチジン類 | |
| MXPA00000856A (es) | Compuestos nuevos de cianoindol inhibidores de la recaptacion de serotonina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. |